Who are Epirubicin+Cyclophosphamide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Epirubicin plus Cyclophosphamide, AC regimen.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/epirubicin-cyclophosphamide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Epirubicin+Cyclophosphamide — Competitive Intelligence Brief

Epirubicin+Cyclophosphamide (Epirubicin+Cyclophosphamide) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (anthracycline + alkylating agent). Area: Oncology.

marketed Chemotherapy combination (anthracycline + alkylating agent) DNA (topoisomerase II for epirubicin; DNA alkylation for cyclophosphamide) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Epirubicin+Cyclophosphamide (Epirubicin+Cyclophosphamide) — The First Affiliated Hospital with Nanjing Medical University. Epirubicin and cyclophosphamide are chemotherapy agents that work together to damage cancer cell DNA and inhibit cell division, commonly used as a combination regimen in breast cancer treatment.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Epirubicin+Cyclophosphamide TARGET	Epirubicin+Cyclophosphamide	The First Affiliated Hospital with Nanjing Medical University	marketed	Chemotherapy combination (anthracycline + alkylating agent)	DNA (topoisomerase II for epirubicin; DNA alkylation for cyclophosphamide)
Epirubicin plus Cyclophosphamide	Epirubicin plus Cyclophosphamide	Shanghai Jiao Tong University School of Medicine	phase 3	Chemotherapy combination (anthracycline + alkylating agent)	DNA (topoisomerase II for epirubicin; DNA alkylation for cyclophosphamide)
AC regimen	AC regimen	UNICANCER	phase 3	Chemotherapy combination (anthracycline + alkylating agent)	DNA (topoisomerase II and DNA alkylation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (anthracycline + alkylating agent) class)

Shanghai Jiao Tong University School of Medicine · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
UNICANCER · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Epirubicin+Cyclophosphamide — Competitive Intelligence Brief. https://druglandscape.com/ci/epirubicin-cyclophosphamide. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab